title: Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases.
abstract: Asparaginases develop innovative "tumor starvation" conditions for all antileukemia treatments; however, administrations are limited by the toxicities of this drug. Patients exhibiting moderate toxicity have optimal treatment outcomes. Certain asparagine synthetase polymorphisms may contribute to severe host toxicities in divergent subsets of patients, whereas others do not. Clinical correlations should be evaluated.
authors.affiliation: Keck School of Medicine, University of Southern California, Los Angeles, California. Children's Hospital Los Angeles, Los Angeles, California. vavramis@chla.usc.edu.
authors.forename: Vassilios I
authors.initials: VI
authors.lastname: Avramis
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D001217:Aspartate-Ammonia Ligase / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001215:Asparaginase; D001217:Aspartate-Ammonia Ligase